Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 517.97
TGTX's Cash-to-Debt is ranked higher than
55% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. TGTX: 517.97 )
Ranked among companies with meaningful Cash-to-Debt only.
TGTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: 517.97
Equity-to-Asset 0.75
TGTX's Equity-to-Asset is ranked higher than
59% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TGTX: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
TGTX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.87 Max: 0.97
Current: 0.75
0.16
0.97
Piotroski F-Score: 3
Altman Z-Score: 1.89
Beneish M-Score: -4.58
WACC vs ROIC
24.26%
-368.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -47750.00
TGTX's Operating Margin % is ranked lower than
97% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. TGTX: -47750.00 )
Ranked among companies with meaningful Operating Margin % only.
TGTX' s Operating Margin % Range Over the Past 10 Years
Min: -141552.63  Med: -39112.17 Max: -15109.21
Current: -47750
-141552.63
-15109.21
Net Margin % -47494.08
TGTX's Net Margin % is ranked lower than
97% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. TGTX: -47494.08 )
Ranked among companies with meaningful Net Margin % only.
TGTX' s Net Margin % Range Over the Past 10 Years
Min: -95121.05  Med: -39055.93 Max: -13472.37
Current: -47494.08
-95121.05
-13472.37
ROE % -81.52
TGTX's ROE % is ranked lower than
74% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. TGTX: -81.52 )
Ranked among companies with meaningful ROE % only.
TGTX' s ROE % Range Over the Past 10 Years
Min: -3919.22  Med: -92.85 Max: -40.04
Current: -81.52
-3919.22
-40.04
ROA % -70.58
TGTX's ROA % is ranked lower than
78% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. TGTX: -70.58 )
Ranked among companies with meaningful ROA % only.
TGTX' s ROA % Range Over the Past 10 Years
Min: -543.33  Med: -90.73 Max: 6.57
Current: -70.58
-543.33
6.57
ROC (Joel Greenblatt) % -5429.91
TGTX's ROC (Joel Greenblatt) % is ranked lower than
81% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. TGTX: -5429.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TGTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -58800  Med: -13407.82 Max: -5429.91
Current: -5429.91
-58800
-5429.91
3-Year Revenue Growth Rate 44.20
TGTX's 3-Year Revenue Growth Rate is ranked higher than
88% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. TGTX: 44.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TGTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: 44.2
0
44.2
3-Year EBITDA Growth Rate -10.60
TGTX's 3-Year EBITDA Growth Rate is ranked lower than
63% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. TGTX: -10.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TGTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -53.6 Max: 73
Current: -10.6
0
73
GuruFocus has detected 2 Warning Signs with TG Therapeutics Inc $TGTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TGTX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

TGTX Guru Trades in

Q2 2015

TGTX Guru Trades in Q2 2015

Jim Simons Sold Out
» More
Q2 2016

TGTX Guru Trades in Q2 2016

Paul Tudor Jones 23,516 sh (New)
» More
Q3 2016

TGTX Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TGTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OCUL, NAS:PTGX, NAS:SELB, OTCPK:CLVLF, NAS:KMDA, NAS:IDRA, NAS:MNKD, NAS:SYRS, OTCPK:PRMCF, OTCPK:MXDHF, NAS:CGEN, NAS:ABEO, NAS:PETX, NAS:CMRX, OTCPK:MDGEF, NAS:CRVS, NAS:SRNE, NAS:SGMO, OTCPK:MTNB, OTCPK:THERF » details
Traded in other countries:NKB2.Germany,
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.

TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy's Laboratories', among others.

Ratios

vs
industry
vs
history
PB Ratio 5.46
TGTX's PB Ratio is ranked lower than
59% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. TGTX: 5.46 )
Ranked among companies with meaningful PB Ratio only.
TGTX' s PB Ratio Range Over the Past 10 Years
Min: 2.51  Med: 5.92 Max: 17.69
Current: 5.46
2.51
17.69
PS Ratio 1420.00
TGTX's PS Ratio is ranked lower than
96% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. TGTX: 1420.00 )
Ranked among companies with meaningful PS Ratio only.
TGTX' s PS Ratio Range Over the Past 10 Years
Min: 558.33  Med: 2012.5 Max: 4670
Current: 1420
558.33
4670
Current Ratio 4.23
TGTX's Current Ratio is ranked higher than
51% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. TGTX: 4.23 )
Ranked among companies with meaningful Current Ratio only.
TGTX' s Current Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.39 Max: 35.5
Current: 4.23
0.06
35.5
Quick Ratio 4.23
TGTX's Quick Ratio is ranked higher than
53% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. TGTX: 4.23 )
Ranked among companies with meaningful Quick Ratio only.
TGTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.39 Max: 35.5
Current: 4.23
0.06
35.5
Days Sales Outstanding 259.34
TGTX's Days Sales Outstanding is ranked lower than
94% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. TGTX: 259.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
TGTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.84  Med: 206.51 Max: 446.64
Current: 259.34
64.84
446.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.90
TGTX's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. TGTX: -27.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TGTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -851.2  Med: -26 Max: 0
Current: -27.9
-851.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.47
TGTX's Price-to-Net-Cash is ranked lower than
52% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. TGTX: 7.47 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TGTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.19  Med: 9.18 Max: 620.4
Current: 7.47
1.19
620.4
Price-to-Net-Current-Asset-Value 5.92
TGTX's Price-to-Net-Current-Asset-Value is ranked higher than
55% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. TGTX: 5.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TGTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.18  Med: 7.8 Max: 3515.58
Current: 5.92
1.18
3515.58
Price-to-Tangible-Book 5.57
TGTX's Price-to-Tangible-Book is ranked lower than
52% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. TGTX: 5.57 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TGTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.65  Med: 7.22 Max: 5631.96
Current: 5.57
0.65
5631.96
Price-to-Median-PS-Value 0.71
TGTX's Price-to-Median-PS-Value is ranked higher than
79% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. TGTX: 0.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TGTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 1.11 Max: 2.05
Current: 0.71
0.32
2.05
Earnings Yield (Greenblatt) % -28.53
TGTX's Earnings Yield (Greenblatt) % is ranked lower than
81% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. TGTX: -28.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TGTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -44.21  Med: 194.4 Max: 1470.1
Current: -28.53
-44.21
1470.1

More Statistics

Revenue (TTM) (Mil) $0.15
EPS (TTM) $ -1.48
Beta2.86
Short Percentage of Float19.77%
52-Week Range $4.10 - 10.50
Shares Outstanding (Mil)54.73

Analyst Estimate

Dec16 Dec18 Dec19
Revenue (Mil $) 0 0 7
EPS ($) -1.28 -1.61 -1.86
EPS without NRI ($) -1.28 -1.61 -1.86
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TGTX

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 

More From Other Websites
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of... Feb 24 2017
[2/23] This Week’s Earnings Revisions Movers Feb 23 2017
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG... Feb 21 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against... Feb 21 2017
TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101... Feb 21 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG... Feb 17 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG... Feb 17 2017
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG... Feb 16 2017
URGENT: Monteverde & Associates PC Encourages TG Therapeutics, Inc. Shareholders with Losses To... Feb 16 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG... Feb 15 2017
TGTX SHAREHOLDER REMINDER: The Law Offices of Vincent Wong Reminds Investors of a Class Action... Feb 15 2017
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against TG... Feb 14 2017
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG... Feb 11 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG... Feb 10 2017
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG... Feb 10 2017
TGTX UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action... Feb 10 2017
TG Therapeutics, Inc. to Present at the 2017 BIO CEO & Investor Conference Feb 09 2017
IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG... Feb 06 2017
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against TG... Feb 06 2017
Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against TG Therapeutics... Feb 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)